The genetic-testing company, which collected DNA data from users, is for sale in bankruptcy court. Now, 27 states and the District of Columbia oppose selling the data without express consent.
Category: Genetics and Heredity
-
23andMe to Be Bought by Regeneron Pharmaceuticals, a Biotech Company, for $256 Million
Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer consumer DNA testing services.
-
A Match Reveals a Secret History
Did I want to expose my mother’s past, or bury it?
-
23andMe Files for Bankruptcy Amid Concerns About Security of Customers’ Genetic Data
The company filed for Chapter 11 bankruptcy to “facilitate a sale process.” Its chief executive stepped down and said she would bid on it.
-
Looking at a Stranger and Seeing Myself
A DNA match revealed my birth mother. Our story began with sacrifice and ended with a rapturous hello.
-
How to Plan a Family Heritage Trip
Online tools are helping Americans travel abroad to discover their ancestry, seek out relatives and obtain documentation for dual citizenship. Here are tips for your journey.
-
What Drugmakers Did Not Tell Volunteers in Alzheimer’s Trials
Genetic tests showed that certain patients were predisposed to brain injuries if they took the drugs. That information remained secret.
-
As 23andMe Struggles, Concerns Surface About Its Genetic Data
A plummet in the company’s valuation and a recent board resignation have raised questions about the future of genetic data collected from millions of customers.
-
Looking for Pet Insurance? Some Dog Breeds Will Cost More to Cover.
Premiums for big dogs and purebreds are generally higher. But as one expert put it, “Every dog can get sick.” Here’s what to know about coverage.
-
Study Suggests Genetics as a Cause, Not Just a Risk, for Some Alzheimers
People with two copies of the gene variant APOE4 are almost certain to get Alzheimer’s, say researchers, who proposed a framework under which such patients could be diagnosed years before symptoms.
-
New Sickle Cell Therapies Will Be Out of Reach Where They Are Needed Most
There is no clear path for African patients to get access to the treatments, which have multimillion-dollar price tags and are highly complex to manufacture and deliver.
-
F.D.A. Approves Drug for Rare Form of A.L.S.
The drug, which will be sold as Qalsody by the pharmaceutical company Biogen, targets a genetic cause of a devastating neurological illness.